Relationship between frailty and Alzheimer's disease biomarkers: A scoping review

Lindsay Wallace; Olga Theou; Kenneth Rockwood; Melissa K. Andrew

doi:10.1016/j.dadm.2018.05.002

Relationship between frailty and Alzheimer's disease biomarkers: A scoping review

Lindsay Wallace, Olga Theou, Kenneth Rockwood, Melissa K. Andrew

Résultat de recherche: Article › examen par les pairs

50 Citations (Scopus)

Résumé

Introduction: Frailty and dementia appear to be closely linked, although mechanisms remain unclear. The objective was to conduct a scoping review of the association between frailty and Alzheimer's disease (AD) biomarkers in humans. Methods: Three databases, PubMed, PsycINFO, and Embase, were searched for articles using the following search terms: “frail elderly” “Alzheimer's disease” “dementia biomarkers” and their synonyms. Inclusion was limited to original research in humans published before 2017, which included a frailty measure and AD biomarker (fluid markers, neuroimaging, and neuropathology). Results: Five hundred twenty-two articles were identified and screened; 10 were included. Most were cross-sectional (n = 6), measured the frailty phenotype (n = 6), and included people with dementia (n = 7). Biomarkers examined were postmortem AD pathology (n = 3), brain atrophy (n = 5), and in vivo fluid markers (n = 2). Eight studies reported that increased frailty was associated with at least one biomarker abnormality. Discussion: Evidence is limited and suffers from design limitations but suggests that frailty and AD biomarkers are closely linked. Longitudinal research examining multiple biomarkers and frailty is warranted.

Langue d'origine	English
Pages (de-à)	394-401
Nombre de pages	8
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	10
DOI	https://doi.org/10.1016/j.dadm.2018.05.002
Statut de publication	Published - janv. 1 2018

Note bibliographique

Funding Information:
This work was supported by the Canadian Consortium on Neurodegeneration in Aging which receives funding from the Canadian Institutes of Health Research and several partner organizations including the Alzheimer Society of Canada, Nova Scotia Health Research Foundation, and the Women's Brain Health Initiative. This study is part of a CCNA investigation into how multi-morbidity modifies the risk of dementia and the patterns of disease expression (Team 14). L.W. is supported by a biomedical doctoral fellowship awarded by the Alzheimer's Society of Canada Research Program in partnership with the CCNA.

Publisher Copyright:
© 2018 The Authors

ASJC Scopus Subject Areas

Clinical Neurology
Psychiatry and Mental health

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1016/j.dadm.2018.05.002

Autres fichiers et liens

Citer

@article{73ae652cf4004fe49bb54aa958d81b38,

title = "Relationship between frailty and Alzheimer's disease biomarkers: A scoping review",

abstract = "Introduction: Frailty and dementia appear to be closely linked, although mechanisms remain unclear. The objective was to conduct a scoping review of the association between frailty and Alzheimer's disease (AD) biomarkers in humans. Methods: Three databases, PubMed, PsycINFO, and Embase, were searched for articles using the following search terms: “frail elderly” “Alzheimer's disease” “dementia biomarkers” and their synonyms. Inclusion was limited to original research in humans published before 2017, which included a frailty measure and AD biomarker (fluid markers, neuroimaging, and neuropathology). Results: Five hundred twenty-two articles were identified and screened; 10 were included. Most were cross-sectional (n = 6), measured the frailty phenotype (n = 6), and included people with dementia (n = 7). Biomarkers examined were postmortem AD pathology (n = 3), brain atrophy (n = 5), and in vivo fluid markers (n = 2). Eight studies reported that increased frailty was associated with at least one biomarker abnormality. Discussion: Evidence is limited and suffers from design limitations but suggests that frailty and AD biomarkers are closely linked. Longitudinal research examining multiple biomarkers and frailty is warranted.",

author = "Lindsay Wallace and Olga Theou and Kenneth Rockwood and Andrew, {Melissa K.}",

note = "Funding Information: This work was supported by the Canadian Consortium on Neurodegeneration in Aging which receives funding from the Canadian Institutes of Health Research and several partner organizations including the Alzheimer Society of Canada, Nova Scotia Health Research Foundation, and the Women's Brain Health Initiative. This study is part of a CCNA investigation into how multi-morbidity modifies the risk of dementia and the patterns of disease expression (Team 14). L.W. is supported by a biomedical doctoral fellowship awarded by the Alzheimer's Society of Canada Research Program in partnership with the CCNA. Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = jan,

day = "1",

doi = "10.1016/j.dadm.2018.05.002",

language = "English",

volume = "10",

pages = "394--401",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Relationship between frailty and Alzheimer's disease biomarkers

T2 - A scoping review

AU - Wallace, Lindsay

AU - Theou, Olga

AU - Rockwood, Kenneth

AU - Andrew, Melissa K.

N1 - Funding Information: This work was supported by the Canadian Consortium on Neurodegeneration in Aging which receives funding from the Canadian Institutes of Health Research and several partner organizations including the Alzheimer Society of Canada, Nova Scotia Health Research Foundation, and the Women's Brain Health Initiative. This study is part of a CCNA investigation into how multi-morbidity modifies the risk of dementia and the patterns of disease expression (Team 14). L.W. is supported by a biomedical doctoral fellowship awarded by the Alzheimer's Society of Canada Research Program in partnership with the CCNA. Publisher Copyright: © 2018 The Authors

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Frailty and dementia appear to be closely linked, although mechanisms remain unclear. The objective was to conduct a scoping review of the association between frailty and Alzheimer's disease (AD) biomarkers in humans. Methods: Three databases, PubMed, PsycINFO, and Embase, were searched for articles using the following search terms: “frail elderly” “Alzheimer's disease” “dementia biomarkers” and their synonyms. Inclusion was limited to original research in humans published before 2017, which included a frailty measure and AD biomarker (fluid markers, neuroimaging, and neuropathology). Results: Five hundred twenty-two articles were identified and screened; 10 were included. Most were cross-sectional (n = 6), measured the frailty phenotype (n = 6), and included people with dementia (n = 7). Biomarkers examined were postmortem AD pathology (n = 3), brain atrophy (n = 5), and in vivo fluid markers (n = 2). Eight studies reported that increased frailty was associated with at least one biomarker abnormality. Discussion: Evidence is limited and suffers from design limitations but suggests that frailty and AD biomarkers are closely linked. Longitudinal research examining multiple biomarkers and frailty is warranted.

AB - Introduction: Frailty and dementia appear to be closely linked, although mechanisms remain unclear. The objective was to conduct a scoping review of the association between frailty and Alzheimer's disease (AD) biomarkers in humans. Methods: Three databases, PubMed, PsycINFO, and Embase, were searched for articles using the following search terms: “frail elderly” “Alzheimer's disease” “dementia biomarkers” and their synonyms. Inclusion was limited to original research in humans published before 2017, which included a frailty measure and AD biomarker (fluid markers, neuroimaging, and neuropathology). Results: Five hundred twenty-two articles were identified and screened; 10 were included. Most were cross-sectional (n = 6), measured the frailty phenotype (n = 6), and included people with dementia (n = 7). Biomarkers examined were postmortem AD pathology (n = 3), brain atrophy (n = 5), and in vivo fluid markers (n = 2). Eight studies reported that increased frailty was associated with at least one biomarker abnormality. Discussion: Evidence is limited and suffers from design limitations but suggests that frailty and AD biomarkers are closely linked. Longitudinal research examining multiple biomarkers and frailty is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85050073529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050073529&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2018.05.002

DO - 10.1016/j.dadm.2018.05.002

M3 - Article

AN - SCOPUS:85050073529

SN - 2352-8729

VL - 10

SP - 394

EP - 401

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

ER -

Relationship between frailty and Alzheimer's disease biomarkers: A scoping review

Résumé

Note bibliographique

ASJC Scopus Subject Areas

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer